VXRT - Conference and earnings call announcements

SOUTH SAN FRANCISCO, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of its management team will participate in the BTIG Virtual Biotechnology Conference taking place virtually July 28, 2026. BTIG Biotechnology Conference 2026Date: Tuesday, July 28, 2026Format: 1x1 MeetingsLocation: VirtualInstitutional Investors interested in meeting with Vaxart management should contact their BTIG representative. About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines base

SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of the management team will participate in the BTIG Infectious Disease Day 2026 on June 16. BTIG Infectious Disease Day 2026Date: Tuesday, June 16, 2026Format: 1x1 MeetingsLocation: Virtual Institutional Investors interested in meeting with Vaxart management should contact their BTIG representative. About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced that members of the management team will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference taking place virtually February 25-26, 2026. Presentation Details: Date and Time: Wednesday, February 25 at 4:00pm ETRegistration and Webcast: Click Here The webcast will be available on the Company's investor relations website at https://investors.vaxart.com for 30 days following the conclusion of the event. The Company will participate in one-on-one

SOUTH SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart or "the Company"), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will participate in the Global BioInnovation Forum, a virtual gathering of senior leaders building and scaling next-generation life science and health innovation companies. Presentation Details: Speakers: Steven Lo, Chief Executive Officer, Sean Tucker, Ph.D., Founder and Chief Scientific Officer, and James F. Cummings, M.D., Chief Medical OfficerDate: Tuesday, January 13, 2026Time: 11:30am PT, 2:30pm ETRegistration and Web

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- SOUTH SAN FRANCISCO, Calif., September 2, 2025 — Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that management will present at the H.C. Wainwright Global Investment Conference taking place September 8-10, 2025. Presentation Details:Date and Time: Monday, September 8 at 12:00 PM ETWebcast: Click Here A live webcast will be available on the Company's investor relations website at https://investors.vaxart.com, and a replay of the presentation will be available for 30 days following the

SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced that members of the management team will present at the Citizens Life Sciences conference taking place May 7-8, 2025. Presentation Details:Date and Time: Wednesday, May 7 at 1:00 PM ETWebcast: Click Here A live webcast will be available on the Company's website at www.vaxart.com, and a replay of the presentation will be available for 30 days following the conclusion of the event. Institutional investors interested in meeting with management during the conference may reach out to their Citizens representative. About VaxartVaxart is a clinical-stage biotechnology company developing

SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2024 in Washington, D.C. on Wednesday, April 3, 2024. The Company has appeared repeatedly at the annual event in Washington, D.C. Presentation Information: Title: Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccinationSpeaker: Dr. Sean TuckerDate: Wednesday, April 3, 2024 Time: 3:10 p.m. ETRoom: 207A About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprie

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present at the World Vaccine Congress Europe 2023 in Barcelona, Spain on Wednesday, October 18 and Thursday, October 19, 2023. Presentation Information: Title: Transmission blocking strategies via oral tablet vaccination and mucosal immune inductionSpeaker: Dr. Sean TuckerDate: Wednesday, October 18, 2023Time: 2:30 p.m. CET / 8:30 a.m. ET Title: Protection against infection from an oral tablet norovirus candidate in humans Speaker: Dr. James F. CummingsDate: Thursday, O

SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced that senior management will participate in a fireside chat at the 2023 Cantor Global Healthcare Conference in New York on Thursday, September 28, 2023 at 2:25 p.m. ET. The webcast of the fireside chat will be available on the Company's Investor Presentations & Events page. A replay will be available on the Company's website following the event. Management will also participate in one-on-one meetings during the conference. Investors interested in a meeting should contact their Cantor representative. About VaxartVaxart is a clinical-stage biotechnology company developing a range of o

SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will make presentations at the World Vaccine Congress Washington 2023 in Washington, D.C. on Wednesday, April 5 and Thursday, April 6, 2023. Presentation Information: Title: Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination Speaker: Dr. Sean TuckerDate: Wednesday, April 5, 2023Time: 4:40 p.m. ET Title: Potent serum and mucosal immune responses to norovirus with Vaxart's oral bivalent norovirus vaccine candidate Speaker: Dr. J

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine & Immunotherapy Congress West Coast 2022 in San Diego on Tuesday, November 29, 2022 at 1:50 p.m. PT / 4:50 p.m. ET. Dr. Tucker will provide an overview of Vaxart's Phase II trial for its oral pill COVID-19 vaccine candidate. Vaxart recently announced positive top-line Phase II clinical study results for its Wuhan S-only COVID-19 pill vaccine candidate. About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delive

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will make separate presentations at the World Vaccine Congress Europe 2022 in Barcelona, Spain on Thursday, October 13, 2022. Presentation Information: Title: Long-lasting nasal mucosal responses in humans to SARS-CoV-2 following oral tablet vaccine administration of non-replicating adenovirus expressing the S and N proteinsSpeaker: Dr. Sean TuckerDate: Thursday, October 13, 2022Time: 11:30 a.m. CET / 5:30 a.m. ET Title: Potent immune responses to norovirus G1.1 evaluated in el

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will be presenting virtually at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022. The pre-recorded presentation will be available on the Company's Events page, accessible here: https://investors.vaxart.com/presentation-events/events, beginning at 7:00 a.m. ET on Monday, September 12, 2022. About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral r

SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2022 in Washington, D.C. on Wednesday, April 20, 2022 at 3:55 p.m. ET.  The title of Dr. Tucker's presentation is "Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination." Dr. Tucker will discuss data supporting the potential benefits of Vaxart's oral tablet COVID-19 vaccine candidate, which is in clinical development. About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will participate in a virtual fireside chat at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022. The fireside chat will be available on the Company's Events & Presentations page, accessible here: https://investors.vaxart.com/events-presentations, beginning at 7:00 a.m. ET on Monday, January 10, 2022. Vaxart's oral tablet COVID-19 vaccine is the only oral COVID-19 vaccine about which ther

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine & Immunotherapy Congress West Coast 2021 in San Diego on Tuesday, November 30, 2021 at 2:40 p.m. PT. Dr. Tucker will provide an overview of Vaxart's development program for its oral tablet COVID-19 vaccine candidate. Vaxart's oral tablet COVID-19 vaccine is the only oral COVID-19 vaccine about which there is clinical data supporting its immunological potential and the only one currently in Phase II clinical trials, which started in October 2021. About VaxartVaxart is a clinica

SOUTH SAN FRANCISCO, Calif., Sept. 22, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ:VXRT), today announced that one of the company's senior scientists, Susan Johnson PhD, will present at both ID Week 2021 and the 15th Vaccine Congress. Dr. Johnson will provide an update on the development of Vaxart's COVID-19 oral vaccine candidate. Information on the two conferences can be found below: ID Week 2021: September 29, 2021 – October 3, 2021 ID Week is the joint annual meeting of the Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, the HIV Medici

SOUTH SAN FRANCISCO, Sept. 20, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ:VXRT) today announced that Chief Executive Officer Andrei Floroiu and Chief Scientific Officer Dr. Sean Tucker will present at the 2021 Cantor Virtual Global Healthcare Conference at 10:40 a.m. ET on Thursday, September 30, 2021.  The presentation will be available by clicking here and on Vaxart's website. The Company will also participate in one-on-one meetings during the conference.   Vaxart's oral tablet COVID-19 vaccine is "The Pill that Moves the Needle" and the only oral COVID-19 vaccine whose potential is backed by clinical data. The Company's oral tablet COVID-19 vaccine candidate has completed phase I trials an

SOUTH SAN FRANCISCO, Calif., Sept. 7, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ:VXRT) today announced that Andrei Floroiu, President and CEO, and Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the H.C. Wainwright 23rd Annual Global Investor Conference taking place Sept. 13-15, 2021. The presentation will be available on demand through the H.C. Wainwright conference portal by clicking here, beginning at 7:00 a.m. ET on Monday, Sept. 13, 2021, and on Vaxart's website. The Company will also participate in one-on-one meetings during the conference. Vaxart's or

SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Andrei Floroiu, CEO and Sean Tucker, CSO of the Vaxart executive team are scheduled to present at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 1:30 p.m. Eastern Time.         Jefferies Virtual Healthcare Conference  Date:Friday, June 4th, 2021 Time:1:30 to 1:55 pm Eastern Time Presenters:Andrei Floroiu, President & CEOSean Tucker, Founder & CSO Webcast:https://wsw.com/webcast/jeff174/vxrt/1906092 Please contact your Jeffer

SOUTH SAN FRANCISCO, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its founder and chief scientific officer, Sean Tucker, Ph.D., will present at the upcoming World Vaccine Congress Washington that will be held virtually from May 4-6, 2021. Dr. Tucker's presentation titled, "Vaxart oral COVID-19 vaccine; hold the ice and the needles," will provide insight into the Company's response and approach to addressing the COVID-19 pandemic with a room temperature oral tablet vaccine that is potentially protective against

Vaxart to provide new data from its Phase I COVID-19 trial Stanford University T-cell expert to discuss cross-protection against variants SOUTH SAN FRANCISCO, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will host a webinar on the importance of T-cell responses for COVID-19 vaccines on Monday, May 3, 2021 at 12:00 p.m. Eastern Time. The progress the United States has made against COVID-19 is imperiled by the rise of new and highly contagious virus strains. Vaxart and the scientific community are working to

SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that management will present at the H.C. Wainwright Global Life Sciences Conference taking place on March 9-10, 2021. The presentation will be available on-demand through the H.C. Wainwright conference portal available here, starting at 7 a.m. ET on Tuesday, March 9, 2021 and on Vaxart’s website after the conference. The Company will also participate in one-on-one investor meetings at the conference. About Vaxart Vaxart is a clinical-stage biotechn